{"url_path":"/sec/bgms/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1130166/0001493152-26-023800-index.html","accession_number":"0001493152-26-023800","cik":"0001130166","ticker":"BGMS","issuer_name":"Bio Green Med Solution, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1130166/0001493152-26-023800-index.html","primary_entity_key":"0001130166","primary_entity_name":"Bio Green Med Solution, Inc."},"word_count":793,"has_tables":true,"body_markdown":"false\n--12-31\nQ1\n0001130166\n\n0001130166\n\n2026-01-01\n2026-03-31\n\n0001130166\n\n2026-05-13\n\n0001130166\n\n2026-03-31\n\n0001130166\n\n2025-12-31\n\n0001130166\n\nBGMS:SixPercentConvertibleExchangeablePreferredStockMember\n\n2026-03-31\n\n0001130166\n\nBGMS:SixPercentConvertibleExchangeablePreferredStockMember\n\n2025-12-31\n\n0001130166\n\nus-gaap:SeriesAPreferredStockMember\n\n2026-03-31\n\n0001130166\n\nus-gaap:SeriesAPreferredStockMember\n\n2025-12-31\n\n0001130166\n\n2025-01-01\n2025-12-31\n\n0001130166\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:PreferredStockMember\n\n2024-12-31\n\n0001130166\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001130166\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001130166\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2024-12-31\n\n0001130166\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001130166\n\n2024-12-31\n\n0001130166\n\nus-gaap:PreferredStockMember\n\n2025-12-31\n\n0001130166\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001130166\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001130166\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-12-31\n\n0001130166\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001130166\n\nus-gaap:PreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:PreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:PreferredStockMember\n\n2025-03-31\n\n0001130166\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001130166\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001130166\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2025-03-31\n\n0001130166\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001130166\n\n2025-03-31\n\n0001130166\n\nus-gaap:PreferredStockMember\n\n2026-03-31\n\n0001130166\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001130166\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001130166\n\nus-gaap:AccumulatedOtherComprehensiveIncomeMember\n\n2026-03-31\n\n0001130166\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001130166\n\n2025-01-24\n2025-01-24\n\n0001130166\n\n2025-05-12\n2025-05-12\n\n0001130166\n\n2025-07-07\n2025-07-07\n\n0001130166\n\n2025-01-24\n\n0001130166\n\nBGMS:FireSafetyEquipmentMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nBGMS:FireSafetyEquipmentMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nBGMS:SafetyAparelMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nBGMS:SafetyAparelMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nBGMS:MaintenanceAndServicingMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nBGMS:MaintenanceAndServicingMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nBGMS:ProjectSupplyAndInstallationMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nBGMS:ProjectSupplyAndInstallationMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:RestrictedStockUnitsRSUMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:SeriesAPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:SeriesAPreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:SeriesDPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:SeriesDPreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:SeriesEPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:SeriesEPreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nBGMS:CommonStockWarrantsMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nBGMS:CommonStockWarrantsMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nBGMS:UnrelatedCustomerMember\n\n2026-03-31\n\n0001130166\n\nBGMS:GeneralAndAdministrativeExpensesMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nBGMS:GeneralAndAdministrativeExpensesMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nBGMS:ResearchAndDevelopmentExpensesMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nBGMS:ResearchAndDevelopmentExpensesMember\n\n2025-01-01\n2025-03-31\n\n0001130166\n\nus-gaap:SeriesEPreferredStockMember\n\n2026-03-31\n\n0001130166\n\nus-gaap:SeriesEPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:SeriesCPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:SeriesDPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nBGMS:SeriesCConvertiblePreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:SeriesDPreferredStockMember\n\n2026-03-31\n\n0001130166\n\nus-gaap:SeriesCPreferredStockMember\n\n2026-03-31\n\n0001130166\n\nBGMS:AprilTwoThousandTwentyFourWarrantsMember\n\n2026-03-31\n\n0001130166\n\nBGMS:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember\nBGMS:PreFundedWarrantsMember\n\n2026-03-31\n\n0001130166\n\nBGMS:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember\nBGMS:CommonStockWarrantsMember\n\n2026-03-31\n\n0001130166\n\nBGMS:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember\nBGMS:SeriesAWarrantsMember\n\n2026-03-31\n\n0001130166\n\nBGMS:AprilTwoThousandTwentyFourSecuritiesPurchaseAgreementMember\nBGMS:SeriesBWarrantsMember\n\n2026-03-31\n\n0001130166\n\nBGMS:PlacementAgentWarrantsMember\n\n2026-03-31\n\n0001130166\n\nBGMS:AprilTwoThousandTwentyFourWarrantsMember\n\n2025-12-31\n\n0001130166\n\nBGMS:December2023PrivatePlacementMember\n\n2026-03-31\n\n0001130166\n\nBGMS:DecemberTwoThousandTwentyThreePrivatePlacementMember\nBGMS:PlacementAgentWarrantsMember\n\n2026-03-31\n\n0001130166\n\nBGMS:December2023PrivatePlacementMember\nus-gaap:WarrantMember\n\n2026-03-31\n\n0001130166\n\nBGMS:December2023PlacementAgencyAgreementMember\n\n2026-03-31\n\n0001130166\n\nBGMS:December2023PrivatePlacementMember\n\n2025-12-31\n\n0001130166\n\nus-gaap:SeriesAPreferredStockMember\nBGMS:UnderwrittenPublicOfferingMember\n\n2017-07-01\n2017-07-31\n\n0001130166\n\nus-gaap:SeriesAPreferredStockMember\n\n2017-07-01\n2017-07-31\n\n0001130166\n\nus-gaap:SeriesAPreferredStockMember\n\n2017-07-31\n\n0001130166\n\nus-gaap:SeriesAPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:ConvertiblePreferredStockMember\n\n2026-03-31\n\n0001130166\n\nus-gaap:ConvertiblePreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001130166\n\nus-gaap:SubsequentEventMember\n\n2026-04-13\n2026-04-13\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\niso4217:MYR\n\nBGMS:Segment\n\nBGMS:Country\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n**(Mark\nOne)**\n\n \n\n \n**☒**\n**QUARTERLY\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe quarterly period ended March 31, 2026**\n\n \n\n**OR**\n\n \n\n \n**☐**\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe transition period from __________________ to __________________**\n\n \n\n**Commission\nfile number 000-50626**\n\n \n\n**Bio\nGreen Med Solution, Inc.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**91-1707622**\n\n(State\nor Other Jurisdiction\n\nof\nIncorporation or Organization)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n\n**Level\n10, Tower 11, Avenue 5, No. 8**\n\n**Jalan\nKerinchi, Kuala Lumpur, Malaysia**\n\n \n**59200**\n\n(Address\nof principal executive offices)\n \n(Zip\nCode)\n\n \n\nRegistrant’s\ntelephone number, including area code: **(908) 955-0526**\n\n \n\n**Cyclacel\nPharmaceuticals, Inc.**\n\n(Former\nname, if changed since last report)\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n \n**Trading\nSymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nCommon\nStock, par value $0.001 per share\n \nBGMS\n \nThe\nNasdaq Stock Market LLC\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer”, “smaller\nreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer ☐\n \nAccelerated\nfiler ☐\n\nNon-accelerated\nfiler ☒\n \nSmaller\nreporting filer ☒\n\n \n \nEmerging\ngrowth company ☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs\nof May 13, 2026, there were 5,519,456 shares of the registrant’s common stock outstanding.\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Bio\nGreen Med Solution, Inc.**\n\n**TABLE\nOF CONTENTS**\n\n \n\n \n \n**Page**\n\n**PART I - FINANCIAL INFORMATION:**"}